137036-54-5

Basic information

• Product Name: (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one
• Synonyms: (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one;(S)-3-aMino-2,3,4,5-tetrahydro-1H-benzazepin-2-one;2H-1-Benzazepin-2-one, 3-aMino-1,3,4,5-tetrahydro-, (3S)-;(S)-3-amino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one;(S)-3-Amino-1,3,4,5-tetrahydro-benzo[b]azepin-2-one
• CAS NO: 137036-54-5
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.22
• Product Categories: PHARMACEUTICAL INTERMEDIATES
• Mol File: 137036-54-5.mol

Chemical Properties

• Boiling Point: 377.524°C at 760 mmHg
• Flash Point: 182.12°C
• Appearance: /
• Density: 1.144g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one(137036-54-5)
• EPA Substance Registry System: (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one(137036-54-5)

Safety Data

• Hazardous Substances Data: 137036-54-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
(3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is used as a synthetic building block for the development of pharmaceutical drugs. Its unique cyclic structure allows for the creation of new compounds with potential therapeutic effects, contributing to the advancement of medicine.
Used in Chemical and Biological Research:
As a research reagent, (3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is utilized in chemical and biological studies to explore its properties and interactions with other molecules. This helps in understanding its potential role in various biological processes and its applicability in drug discovery.
Used in Drug Discovery:
(3S)-Amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is used as a valuable tool in drug discovery due to its potential applications in the treatment of various diseases and disorders. Its unique structure allows for the design and synthesis of new compounds with therapeutic potential, aiding in the development of novel treatments for unmet medical needs.

InChI:InChI=1/C10H12N2O/c11-8-6-5-7-3-1-2-4-9(7)12-10(8)13/h1-4,8H,5-6,11H2,(H,12,13)/t8-/m0/s1

Upstream product

• 602307-76-6 (5a-hydroxy-1-methoxy-2-oxo-2,3,4,5,5a,9a-hexahydro-1H-benzo[b]azepin-3-yl)-carbamic acid benzyl ester 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 140700-64-7 3-iodo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 97278-68-7 3-azido-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepine 
• 216753-94-5 (S)-4-(2-Amino-phenyl)-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 156247-61-9 (S)-tert-butyl (2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)carbamate 
• 86499-35-6 3-amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 

Downstream Products

• 145554-02-5 3-benzyloxycarbonylamino-3-methyl-N-[2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3(R)-yl]-butanamide 
• 958075-64-4 (2R,3R,4S,5R,6E)-7-cyclopentyl-3,4,5-trihydroxy-2-methoxy-N-[(3S)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]hept-6-enamide 
• 958075-59-7 (2R,3R,4S,5R,6E)-3,4,5-trihydroxy-2-methoxy-8,8-dimethyl-N-[(3S)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]non-6-enamide 
• 958075-63-3 (3S)-3-amino-7-phenyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one hydrochloride 
• 958075-62-2 tert-butyl [(3S)-2-oxo-7-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]carbamate 
• 1539309-79-9 {(S)-1-[(S)-1-(5-fluoro-2-methoxy-benzyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3yl carbamoyl]-ethyl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Practical synthesis of (-)-α-aminobenzolactam via nitration-cyclization of L-homophenylalanine ethyl ester

A practical synthesis of chiral (-)-α-aminobenzolactam (2) is described. The target compound (2) was prepared from commercially available L-homophenylalanine ethyl ester hydrochloride (LHPE-HCl 1) with a highly enantiomeric purity (>98% e.e.) by employing

Synthesis of optically active α-aminobenzolactam via an oxidative-cyclization reaction

A convergent pathway for the asymmetric synthesis of (-)-α-aminobenzolactam 1 is described. For the first time, the key intermediate N-methoxybenzolactam 8 was prepared from L-homophenylalanine ethyl ester hydrochloride (LHPE·HCl) 5 by employing an oxidat

Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry: NMR Studies of Amino Acid-Derived Organozinc Reagents

Protected phenylalanines 23 (seven examples), homophenylalanines 7 (eight examples), and bishomophenylalanines 8 (seven examples) have been prepared by palladium-catalyzed coupling of the amino acid-derived organozinc reagents 13, 5, and 6, respectively, with aryl iodides. While the reactions of the zinc reagent 13 may be conducted in both THF and DMF as solvent, the results obtained in DMF are generally superior. In the case of the reagents 5 and 6 the results are far superior in DMF. NMR investigations on the structure of the zinc reagents 13 in THF suggest that there is strong intramolecular coordination of the urethane carbonyl group, whereas in DMF this interaction is completely suppressed.

An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-benzazepin-2-one

Two approaches for the asymmetric preparation of (-)- or (+)-α-aminobenzlactam 1 are described.One route is based on the asymmetric hydrogenation of enamide 5 and the other on the racemization/resolution of (+/-)-1.

A novel 3-substituted benzazepinone growth hormone secretagogue (L- 692,429)

The 3-substituted benzazepinone, L-692,429 (compound 1), is the prototype compound of a novel class of compounds that stimulate release of growth hormone (GH). The molecule evolved from efforts to identify a non-peptide mimic of the growth hormone-releasing hexapeptide, GHRP-6. Compound 1 is prepared by sequential attachment of dimethyl-β-alanine and 2'- biphenylyltetrazole side chains to a chiral 3-aminobenzolactam nucleus. Comparison of the biological activity of 1 with the corresponding six- and eight-membered lactam analogs shows the seven-membered benzazepinone skeleton to be preferred. Molecular modeling of the structurally diverse GH secretagogues, L-692,429 and GHRP-6, was performed.